Fernando Fervenza
Mayo Clinic, Rochester, MN · Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fernando Fervenza as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06676579 · Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)Mayo Clinic · recruiting · IgA Nephropathy (IgAN) · principal investigator
- Ph2NCT06295770 · Obinutuzumab in Treatment of Fibrillary GlomerulonephritisMayo Clinic · recruiting · Fibrillary Glomerulonephritis · principal investigator
- Ph2NCT05654506 · Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune DepositsMayo Clinic · active not recruiting · Proliferative Glomerulonephritis With Monoclonal IgG Deposits · principal investigator
- Ph2NCT04983888 · Obinutuzumab in Primary FSGSMayo Clinic · completed · Primary Focal Segmental Glomerulosclerosis · principal investigator
- Ph2NCT04868838 · Daratumumab to Treat Active Lupus NephritisMayo Clinic · active not recruiting · Lupus Nephritis · principal investigator
- Ph3NCT02282930 · Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionMayo Clinic · completed · Progressive IgA Nephropathy, Proteinuria · principal investigator
- N/ANCT01093781 · Aliskiren in Patients With Idiopathic Membranous NephropathyMayo Clinic · withdrawn · Idiopathic Membranous Nephropathy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- PULSE DEXAMETHASONE IN FOCAL SEGMENTAL GLOMERULOSCLEROSISM01RR000585 · NCRR · MAYO CLINIC ROCHESTER · fiscal years 2004 to 2005 · $474 awarded in 2005Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:51 UTC. The ranking covers the 200 most relevant of 37 PubMed records, and a shared surname and initials can bring in a namesake. All 37 on PubMed
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis.N Engl J Med · 20102,080 citationsRCR 63.1
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.Arthritis Rheum · 20121,108 citationsRCR 33.1
- Efficacy of remission-induction regimens for ANCA-associated vasculitis.N Engl J Med · 2013571 citationsRCR 20.0
- Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.N Engl J Med · 2019511 citationsRCR 24.0
- Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.Am J Respir Crit Care Med · 2006303 citationsRCR 9.2
- Pirfenidone for diabetic nephropathy.J Am Soc Nephrol · 2011259 citationsRCR 7.1
- A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.J Am Soc Nephrol · 2017243 citationsRCR 9.8
- A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.Kidney Int · 2011217 citationsRCR 5.7
- Rituximab treatment of idiopathic membranous nephropathy.Kidney Int · 2008216 citationsRCR 6.2
- Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.Ann Rheum Dis · 2016202 citationsRCR 8.8